Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 1688 results for carers

  1. Sabizabulin for treating COVID-19 TS ID 11814

    Awaiting development [GID-TA11226] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808

    Awaiting development [GID-TA11200] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838

    Awaiting development [GID-TA11275] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839

    Awaiting development [GID-TA11276] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190

    Awaiting development [GID-TA11283] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666

    Awaiting development [GID-TA11182] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523

    Awaiting development [GID-TA11114] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781

    Awaiting development [GID-TA11110] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

    Awaiting development [GID-TA11053] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690

    Awaiting development [GID-TA11073] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

    Awaiting development [GID-TA11049] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763

    Awaiting development [GID-TA11048] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]

    Awaiting development [GID-TA11011] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]

    Awaiting development [GID-TA10967] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development